Literature DB >> 20852098

Genetics and vaccine efficacy: host genetic variation affecting Marek's disease vaccine efficacy in White Leghorn chickens.

S Chang1, J R Dunn, M Heidari, L F Lee, J Song, C W Ernst, Z Ding, L D Bacon, H Zhang.   

Abstract

Marek's disease (MD) is a T-cell lymphoma disease of domestic chickens induced by MD virus (MDV), a naturally oncogenic and highly contagious cell-associated α-herpesvirus. Earlier reports have shown that the MHC haplotype as well as non-MHC genes are responsible for genetic resistance to MD. The MHC was also shown to affect efficiency of vaccine response. Using specific-pathogen-free chickens from a series of 19 recombinant congenic strains and their 2 progenitor lines (lines 6(3) and 7(2)), vaccine challenge experiments were conducted to examine the effect of host genetic variation on vaccine efficacy. The 21 inbred lines of White Leghorns share the same B*2 MHC haplotype and the genome of each recombinant congenic strain differs by a random 1/8 sample of the susceptible donor line (7(2)) genome. Chickens from each of the lines were divided into 2 groups. One was vaccinated with turkey herpesvirus strain FC126 at the day of hatch and the other was treated as a nonvaccinated control. Chickens of both groups were inoculated with a very virulent plus strain of MDV on the fifth day posthatch. Analyses of the MD data showed that the genetic line significantly influenced MD incidence and days of survival post-MDV infection after vaccination of chickens (P<0.01). The protective indices against MD varied greatly among the lines with a range of 0 up to 84%. This is the first evidence that non-MHC host genetic variation significantly affects MD vaccine efficacy in chickens in a designed prospective study.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20852098     DOI: 10.3382/ps.2010-00740

Source DB:  PubMed          Journal:  Poult Sci        ISSN: 0032-5791            Impact factor:   3.352


  7 in total

1.  Expression kinetics of chicken β2-microglobulin and Class I MHC in vitro and in vivo during Marek's disease viral infections.

Authors:  Chuan Yu; Qiu Liu; Aijian Qin; Xuming Hu; Wencai Xu; Kun Qian; Hongxia Shao; Wenjie Jin
Journal:  Vet Res Commun       Date:  2013-08-06       Impact factor: 2.459

2.  Characterization of Copy Number Variation's Potential Role in Marek's Disease.

Authors:  Lingyang Xu; Yanghua He; Yi Ding; Guirong Sun; Jose Adrian Carrillo; Yaokun Li; Mona M Ghaly; Li Ma; Huanmin Zhang; George E Liu; Jiuzhou Song
Journal:  Int J Mol Sci       Date:  2017-05-09       Impact factor: 5.923

3.  Integrated Core Proteomics, Subtractive Proteomics, and Immunoinformatics Investigation to Unveil a Potential Multi-Epitope Vaccine against Schistosomiasis.

Authors:  Abdur Rehman; Sajjad Ahmad; Farah Shahid; Aqel Albutti; Ameen S S Alwashmi; Mohammad Abdullah Aljasir; Naif Alhumeed; Muhammad Qasim; Usman Ali Ashfaq; Muhammad Tahir Ul Qamar
Journal:  Vaccines (Basel)       Date:  2021-06-16

4.  Genome-wide copy number variant analysis in inbred chickens lines with different susceptibility to Marek's disease.

Authors:  Juan Luo; Ying Yu; Apratim Mitra; Shuang Chang; Huanmin Zhang; George Liu; Ning Yang; Jiuzhou Song
Journal:  G3 (Bethesda)       Date:  2013-02-01       Impact factor: 3.154

5.  Genetic assessment of inbred chicken lines indicates genomic signatures of resistance to Marek's disease.

Authors:  Lingyang Xu; Yanghua He; Yi Ding; George E Liu; Huanmin Zhang; Hans H Cheng; Robert L Taylor; Jiuzhou Song
Journal:  J Anim Sci Biotechnol       Date:  2018-09-13

6.  Marek's disease vaccines-induced differential expression of known and novel microRNAs in primary lymphoid organ bursae of White Leghorn.

Authors:  Lei Zhang; Chen Zhu; Mohammad Heidari; Kunzhe Dong; Shuang Chang; Qingmei Xie; Huanmin Zhang
Journal:  Vet Res       Date:  2020-02-24       Impact factor: 3.683

7.  Association of the chicken MHC B haplotypes with resistance to avian coronavirus.

Authors:  Ghida R Banat; Suzana Tkalcic; Jennifer A Dzielawa; Mark W Jackwood; Miguel D Saggese; Linda Yates; Renee Kopulos; W E Briles; Ellen W Collisson
Journal:  Dev Comp Immunol       Date:  2012-11-23       Impact factor: 3.636

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.